Junshi Biosciences
[1877:HK]
Has a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic, autoimmune, neurological, and infectious diseases. Product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai and Suzhou. JS001, or toripalimab, is approved by the NMPA and the first marketed anti-PD-1 mAb antibody self-developed by a PRC company. [more information]